Arterial stiffness is increased in patients with type 1 diabetes without cardiovascular disease: A potential role of low-grade inflammation

Diabetes Care

Volumn 35, Issue 5, 2012, Pages 1083-1089

  Llauradó, Gemma ^a   Ceperuelo Mallafré, Victòria ^b,c   Vilardell, Carme ^d   Simó, Rafael ^e   Freixenet, Núria ^a   Vendrell, Joan ^c   González Clemente, José Miguel ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^d Althaia   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTERIAL STIFFNESS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PULSE WAVE; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; SEX FACTORS; VASCULAR STIFFNESS; YOUNG ADULT;

EID: 84862063332     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1475     Document Type: Article

References (36)

1. Daneman D. Type 1 diabetes. Lancet 2006;367:847-858 (Pubitemid 43363372)
2. Libby P, Nathan DM, Abraham K, et al.; National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 2005;111:3489-3493 (Pubitemid 40923404)
3. Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH. Aortic stiffness: current understanding and future directions. J Am Coll Cardiol 2011;57:1511-1522
4. Laurent S, Cockcroft J, Van Bortel L, et al.; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-2605 (Pubitemid 44627304)
5. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318-1327
6. Kaptoge S, Di Angelantonio E, Lowe G, et al.; Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-140
7. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695
8. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-1772 (Pubitemid 30213096)
9. Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality: a population-based, prospective study. Thromb Haemost 2006;95:511-518
10. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008;5:e78
11. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia 2005;48:370-378 (Pubitemid 40543311)
12. Nakhai-Pour HR, Grobbee DE, Bots ML, Muller M, van der Schouw YT. C-reactive protein and aortic stiffness and wave reflection in middle-aged and elderly men from the community. J Hum Hypertens 2007;21:949-955 (Pubitemid 350162703)
13. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005;46:1118-1122 (Pubitemid 41533013)
14. Lilitkarntakul P, Dhaun N, Melville V, et al. Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity. Atherosclerosis 2011;216:217-225
15. Ferreira I, Boreham CA, Twisk JW, et al. Clustering of metabolic syndrome risk factors and arterial stiffness in young adults: the Northern Ireland Young Hearts Project. J Hypertens 2007;25:1009-1020 (Pubitemid 46573120)
16. González-Clemente JM, Giménez-Pérez G, Richart C, et al. The tumour necrosis factor (TNF)-alpha system is activated in accordance with pulse pressure in normotensive subjects with type 1 diabetes mellitus. Eur J Endocrinol 2005;153:687-691 (Pubitemid 41672415)
17. Arain FA, Kuniyoshi FH, Abdalrhim AD, Miller VM. Sex/gender medicine: the biological basis for personalized care in cardiovascular medicine. Circ J 2009;73:1774-1782
18. Mancia G, De Backer G, Dominiczak A, et al.; The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension; The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536
19. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421
20. American Diabetes Association. Standards of medical care in diabetes: 2011. Diabetes Care 2011;34(Suppl. 1):S11-S61
21. Lacy PS, O'Brien DG, Stanley AG, Dewar MM, Swales PP, Williams B. Increased pulse wave velocity is not associated with elevated augmentation index in patients with diabetes. J Hypertens 2004;22:1937-1944 (Pubitemid 39336676)
22. Vastagh I, Horváth T, Nagy G, et al. Evolution and predictors of morphological and functional arterial changes in the course of type 1 diabetes mellitus. Diabetes Metab Res Rev 2010;26:646-655
23. Schalkwijk CG, Poland DC, van Dijk W, et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999;42:351-357 (Pubitemid 29111443)
24. Jenkins AJ, Rothen M, Klein RL, et al.; DCCT/EDIC Research Group. Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J Diabetes Complications 2008;22:153-163 (Pubitemid 351539060)
25. Kilpatrick ES, Keevil BG, Jagger C, Spooner RJ, Small M. Determinants of raised C-reactive protein concentration in type 1 diabetes. QJM 2000;93:231-236 (Pubitemid 30198960)
26. Mackness B, Hine D, McElduff P, Mackness M. High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis 2006;186:396-401
27. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB; European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-466 (Pubitemid 27077826)
28. Lanza GA, Pitocco D, Navarese EP, et al. Association between cardiac autonomic dysfunction and inflammation in type 1 diabetic patients: effect of beta-blockade. Eur Heart J 2007;28:814-820 (Pubitemid 47343595)
29. Nowak M, Wielkoszyński T, Marek B, et al. Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy. Clin Exp Med 2010;10:185-192
30. Tsioufis C, Dimitriadis K, Selima M, et al. Low-grade inflammation and hypoadiponectinaemia have an additive detrimental effect on aortic stiffness in essential hypertensive patients. Eur Heart J 2007;28:1162-1169 (Pubitemid 47343887)
31. Colhoun HM, Schalkwijk C, Rubens MB, Stehouwer CD. C-reactive protein in type 1 diabetes and its relationship to coronary artery calcification. Diabetes Care 2002;25:1813-1817 (Pubitemid 41071092)
32. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:932-943 (Pubitemid 40627836)
33. Schram MT, Chaturvedi N, Schalkwijk C, et al.; EURODIAB Prospective Complications Study. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2003;26:2165-2173 (Pubitemid 41184269)
34. Astrup AS, Tarnow L, Pietraszek L, et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care 2008;31:1170-1176
35. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002;39:10-15 (Pubitemid 34098081)
36. Gordin D, Wadén J, Forsblom C, et al.; FinnDiane Study Group. Pulse pressure predicts incident cardiovascular disease but not diabetic nephropathy in patients with type 1 diabetes (The FinnDiane Study). Diabetes Care 2011;34:886-891